Kalaris Therapeutics, Inc. (KLRS) stock
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Earnings
Kalaris Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Kalaris Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 16, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | – | – | -$0.46 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | – | – | -$0.46 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 17, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | -$0.64 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | -$0.61 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | -$2.52 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 18, 2025during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | – | – | -$0.48 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | – | – | -$0.44 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 15, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | – | – | -$0.50 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | – | – | -$0.69 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | – | – | -$0.69 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 10, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 5, 2021before the open | – | – | -$0.72 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Sep 2, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Kalaris Therapeutics guided for has been reported
Guidance history
Every forecast Kalaris Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 3, 2023 | operating expenses | FY2023 | $150.00M – $170.00M | Reaffirmed |
| Feb 15, 2023 | operating expenses | FY2023 | $150.00M – $170.00M | New |
| Nov 3, 2022 | operating expenses | FY2022 | $130.00M – $145.00M | Reaffirmed |
| Aug 4, 2022 | operating expenses | FY2022 | $130.00M – $145.00M | Reaffirmed |
| Feb 10, 2022 | operating expenses | FY2022 | $130.00M – $145.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Kalaris Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- News
- Update
- Update
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?